Navigation Links
Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell

Researchers at the Albert Einstein College of Medicine and the German Cancer Research Institute have shown how protein synthesis is targeted to certain regions of a cell--a process crucial for the cellular motility that governs nerve growth, wound healing and cancer metastasis. Their study appears in the November 24 issue of the journal Nature.

Led by Drs. Robert Singer and Dr Stefan Huettelmaier, the research team focused on migrating fibroblast cells important in wound healing. To move towards a wound, these cells manufacture the protein actin, which polymerizes into long filaments that push the cell's membrane outward to form protrusions.

The team's previous work showed how newly formed actin messenger RNA molecules find their way to the cell's periphery: A protein called ZBP1 binds to the messenger RNA and "escorts" it out of the fibroblast nucleus and into the cytoplasm. On reaching the cell's periphery, the messenger RNA is translated into actin protein responsible for cell motility.

This new study reveals another key role for ZBP1: Not only does ZBP1 bind to actin messenger RNA and guide it to the cell's periphery, but it also helps regulate where in the cell the messenger RNA is translated into actin.

"The ZBP1 bound to actin's messenger RNA acts like a lock to prevent it from being translated into protein before reaching its destination," explains Dr. Singer. "On arriving at the cell periphery, the messenger RNA/ZBP1 complex encounters an enzyme, the protein kinase Src, which is active only in that part of the cell. Src adds a phosphate group to ZBP1 close to where it binds to messenger RNA, and this phosphorylation reaction detaches ZBP1 from the actin messenger RNA--unlocking the messenger RNA so it can now be translated into the actin protein that makes cell movement possible."

Understanding how actin synthesis is spatially regulated in motile cells could lead to new cancer therapies. "In cancer," says Dr. Singer , "we know that expression of ZBP1 correlates with benign tumors, while suppression of ZBP1 is associated with metastasis--when motile cancer cells break off from the primary tumor and invade other areas of the body. So a drug that could force tumor cells to express ZBP1 might prevent cancers from spreading."

In addition to Dr. Singer, other Einstein researchers involved in the study are Dr. John Condeelis, professor and co-chair with Dr. Singer of Einstein's Department of Anatomy and Structural Biology, Daniel Zenklusen, Mike Lorenz, XiuHua Meng, and Jason Dictenberg of that department, Gary J. Bassell of the Department of Neuroscience at Einstein, and Dr. Marcell Lederer, now in Dr. Huettelmaier's laboratory of Martin-Luther-University of Halle, Germany.


'"/>

Source:Albert Einstein College of Medicine


Related biology news :

1. Einstein researchers identify new way that bacteria develop resistance to antibiotics
2. Study by Einstein researchers could lead to a novel strategy for treating obesity
3. Einstein researchers take the pulse of a gene in living cells
4. Einstein researchers demonstrate a novel approach to treating AIDS
5. Einsteins tea leaves inspire new blood separation technique
6. Wisconsin scientists grow critical nerve cells
7. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
8. UAB scientists discover the origin of a mysterious physical force
9. Fox Chase Cancer Center scientists identify immune-system mutation
10. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
11. U-M scientists find genes that control growth of common skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/21/2017)... 2017 Der weltweite Biobanking-Sektor wird ... einem Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen ... gilt, um diese Prognose zu realisieren. ... Zu den ... finanziellen Mittel für die Biobank, die Implementierung Zeit sparender ...
(Date:2/13/2017)... FRANCISCO , Feb. 13, 2017  RSA ... centralized platform that is designed to enhance fraud ... latest release in the RSA Fraud & Risk ... enable organizations to leverage additional insights from internal ... tools to better protect their customers from targeted ...
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
Breaking Biology News(10 mins):
(Date:3/23/2017)... Research and Markets has announced the addition of the ... ... The Global Market for Bioproducts Should Reach $714.6 Billion by ... 8.9%, This research report quantifies the two ... segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and herbal/botanicals), biocomposite materials, ...
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
(Date:3/23/2017)... PARK, Calif., March 23, 2017  BioPharmX Corporation ... products for the dermatology market, today reported financial ... 31, 2017, and will provide an update on ... the year. "We are pleased to ... year for BioPharmX," said President Anja Krammer. "We ...
(Date:3/23/2017)... -- Kineta, Inc., a biotechnology company focused on ... today announced the discovery and characterization of several ... interferon response factor 3 (IRF3) via RIG-I like ... in a murine colon carcinoma mouse model.  Furthermore, ... regression to initial drug treatment were resistant to ...
Breaking Biology Technology: